Nov 29, 2018
Prometic bags USD 50 Million stock sale option to ease a cash crunch Prometic Life Sciences got into an agreement for selling USD 50 million in stock. This gives Prometic a way to escape its current financial pressures. Canada-based Prometic was asked by the FDA to make and validate process changes for Ryplazim, a c...
Read More...
Discover How Learning Disability Treatment Landscape is Evolving with the Emergence of Digital Assistant Technologies
Jul 04, 2025
A New Era for Multiple Myeloma Treatment: Bispecific Antibodies Enter the Fray
Jun 10, 2025
LEQEMBI: A New Hope for Alzheimer’s Disease Patients
Feb 12, 2025
-Agonist.png "Toll-like Receptors Agonist")
Newsletter/Whitepaper